Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
AssigneeWyeth
InventorsCharles Zacharchuk, Susan Quinn, Patricia Martins, Lee Greenberger, Ante Lundberg
Life of this patent
Estimating the term…
Abstract
This invention discloses method of treating or inhibiting cancer in a human having at least one of an Exon 19 del E746-A750 and/or an Exon 21 point mutation comprising administering to said human gefitinib and/or iressa alone or in combination with other cytotoxic agents or chemotherapeutic agents and an effective amount of EGFR kinase inhibitor.
Claims7
A method of treating or inhibiting cancer in a human having at least one of an Exon 19 del E746-A750 and/or an Exon 21 point mutation comprising administering to said human gefitinib or iressa alone or in combination with other cytotoxic agents or chemotherapeutic agents and an effective amount of EGFR kinase inhibitor.
Dependencies are inferred from the claim text.